Literature DB >> 21900219

Endoscopic therapy of esophageal premalignancy and early malignancy.

Thomas B Nealis1, Kay Washington, Rajesh N Keswani.   

Abstract

Esophageal adenocarcinoma (EAC) is an often deadly cancer with a rising incidence in Western countries. Chronic gastroesophageal reflux disease is associated with the metaplastic transformation of normal squamous epithelium to premalignant specialized intestinal metaplasia within the esophagus (Barrett's esophagus). Barrett's esophagus may progress to low-grade dysplasia (LGD), high-grade dysplasia (HGD), or even EAC. Although nondysplastic Barrett's esophagus progresses to EAC at a rate of 0.5% per year, rates of progression for true LGD and HGD are significantly higher. Treatment is mandatory for HGD and may be appropriate in select patients with nondysplastic Barrett's esophagus and many with LGD. Thus, accurate pathologic assessment is necessary before considering endoscopic therapy. Previously, only esophagectomy was offered to patients with HGD or EAC. However, esophagectomy has significant morbidity and mortality, and therefore endoscopic therapies have been advocated for early Barrett's neoplasia. These methods include endoscopic mucosal resection (EMR) and ablative techniques. Ablation techniques include argon plasma coagulation, multipolar electrocoagulation, laser therapy, photodynamic therapy, radiofrequency ablation, and cryotherapy. Of these, radiofrequency ablation has experienced the greatest adoption for the treatment of dysplastic Barrett's esophagus because of excellent published outcomes. The use of EMR to resect suspicious areas or raised lesions is mandatory to provide histology. In contrast, ablation techniques such as radiofrequency ablation have been shown to effectively eradicate large areas of dysplastic tissue with relative ease but do not allow for histologic assessment of the treated area. Combination EMR with radiofrequency ablation is thus advocated to resect visible lesions via EMR (providing histology) and ablate the remainder of the Barrett's esophagus. As always, the appropriate treatment is best determined after careful discussion with patients in a multidisciplinary environment. However, endoscopic therapy offers an attractive alternative to esophagectomy for early Barrett's neoplasia.

Entities:  

Mesh:

Year:  2011        PMID: 21900219     DOI: 10.6004/jnccn.2011.0073

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  5 in total

1.  Endoscopic ultrasonography for staging of T1a and T1b esophageal squamous cell carcinoma.

Authors:  Long-Jun He; Hong-Bo Shan; Guang-Yu Luo; Yin Li; Rong Zhang; Xiao-Yan Gao; Guo-Bao Wang; Shi-Yong Lin; Guo-Liang Xu; Jian-Jun Li
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

2.  Does delayed esophagectomy after endoscopic resection affect outcomes in patients with stage T1 esophageal cancer? A propensity score-based analysis.

Authors:  Shengfei Wang; Yangle Huang; Juntao Xie; Lingdun Zhuge; Longlong Shao; Jiaqing Xiang; Yawei Zhang; Yihua Sun; Hong Hu; Sufeng Chen; Toni Lerut; James D Luketich; Jie Zhang; Haiquan Chen
Journal:  Surg Endosc       Date:  2017-09-15       Impact factor: 4.584

3.  Endoscopic mucosal resection for staging and treatment of early esophageal carcinoma: a single institution experience.

Authors:  Justin T Huntington; Jon P Walker; Michael P Meara; Jeffrey W Hazey; W Scott Melvin; Kyle A Perry
Journal:  Surg Endosc       Date:  2014-12-04       Impact factor: 4.584

Review 4.  Efficacy and Safety of Four Different Endoscopic Treatments for Early Esophageal Cancer: a Network Meta-analysis.

Authors:  Wenyu Hu; Jia Yu; Nan Yao; Xiaotong Li; Yixue Yang; Ling Wang; Mengzi Sun; Yinpei Guo; Han Wang; Shoumeng Yan; Bo Li
Journal:  J Gastrointest Surg       Date:  2022-02-22       Impact factor: 3.452

Review 5.  Management controversies in Barrett's oesophagus.

Authors:  L Max Almond; Hugh Barr
Journal:  J Gastroenterol       Date:  2013-06-05       Impact factor: 7.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.